| Autor: |
Knellwolf, Anne-Laure, Deligne, Jean, Chiarotti, Flavia, Auleley, Guy-Robert, Palmieri, Serena, Boisgard, Claudine, Panei, Pietro, Autret-Leca, Elisabeth |
| Předmět: |
|
| Zdroj: |
European Journal of Clinical Pharmacology; Mar2008, Vol. 64 Issue 3, p311-317, 7p, 2 Charts, 2 Graphs |
| Abstrakt: |
The aim of the study was to describe the prevalence and utilization patterns of methylphenidate (MPH) in children and adolescents in France. This was a population-based retrospective study in which the cohort consisted of patients for whom data were extracted from the dispensation drug claims database of the national health insurance (NHI) fund for self-employed workers. Annual prevalence of MPH use was evaluated on patients aged 6–18 years who were reimbursed for at least one MPH prescription a year. Between January 2004 and June 2005, features of MPH medication and user profile were described for the “new starters” having a screening period of 1 year without receiving a MPH prescription and a follow-up ≥12 months. Time to interruption of MPH regular use was analysed by Kaplan-Meier survival analysis. Mean duration of exposure to MPH treatment was computed with the 95% confidence interval (CI). Annual prevalence of MPH per 1000 persons was 1.1 in 2003, 1.5 in 2004 and 1.8 in 2005 (relative increase of 63.5%). New starters ( n = 447) received their first MPH prescription through the hospital (65.1%) or through private practitioners (34.9%). The user profiles were: short (16.6%), occasional (33.8%) and regular (49.6%). Among the new starters, the median time to interruption of MPH regular use was 10.2 months (95% CI: 7.9–12.4). The mean duration of exposure to MPH treatment was: occasional (4.9 months, 95% CI: 4.3–5.5) and regular (25.7 months, 95% CI: 24.6–26.8). Although there is a low prevalence of MPH use in France, this survey revealed a wide profile of users and heterogeneous use patterns. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink